Serum C-reactive protein level in COPD patients stratified according to GOLD 2011 grading classification

Lin, Yihua; Wang, Wanyu; Hu, Shaojun; Yan, Shi

doi:10.12669/pjms.326.10905

Cited by 5 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was further established that patients presenting with acute exacerbation had higher levels of acute phase proteins like CRP than stable patients [20] . In our study, CRP is inversely correlated with FEV1(r= -0.284, p=0.004) that was statistically significant which is in accordance with study conducted by SJ Wu,PChen et al [21] , Andrea Corsonello et al [22] and Yihua Lin [23] who also found negative correlation of CRP with FEV1. Study by Rakesh Kumar and P Nigam [24] concluded that correlation of CRP with FEV1 was negative in cases presenting as acute exacerbation.…”

Section: Discussionsupporting

confidence: 91%

Study of Prognostic Association of C-Reactive Protein (A Biomarker) with Clinically Important Predictors of Outcome in Stable and Unstable COPD Patients

2016

AIMDR

View full text Add to dashboard Cite

Background: COPD is characterized by persistent airflow limitation that is progressive and is associated with enhanced chronic inflammatory response in the airways to noxious particles or gases. It has both systemic and pulmonary effects. Since COPD deaths estimated to increase by 30% in next 10 years, cost of treatment will be a heavy burden on global economy. The costs are proportional to pulmonary and extra pulmonary components of the disease. Methods: In this study, we examined 100 patients of COPD, out of which 80 were stable and 20 were unstable. Results: CRP levels were found to be increased in cases more than in controls (13.55+10.83 vs. 2.07+0.82 mg/lit, p<0.001), the levels being higher in unstable patients than in stable patients (33.78+7.74 vs. 8.50+1.81 mg/lit, p<0.001). We also submitted the patients to MMRC dyspnoea scale and found that CRP is positively correlated with MMRC dyspnoea scale (r=0.638, p<0.001) and was inversely correlated with 6-minute walk distance (r= -0.364, p<0.001). There was a significant positive correlation of CRP with BODE index (r=0.780, p<0.001). Conclusion: The study is valuable in detecting the severity of COPD cases both in stable and unstable conditions and to forecast the future morbidity and mortality outcome of such cases.

show abstract

Section: Discussionsupporting

confidence: 91%

Study of Prognostic Association of C-Reactive Protein (A Biomarker) with Clinically Important Predictors of Outcome in Stable and Unstable COPD Patients

2016

AIMDR

View full text Add to dashboard Cite

show abstract

“…The overall prevalence of spirometry-defined COPD was 8.6%, accounting for 99.9 million people with COPD in China [2]. More and more studies have shown that COPD is not only a respiratory inflammatory condition, but also one disease characterized by low-grade and chronic systemic inflammation with many extrapulmonary manifestations [3,4]. The systemic inflammation is associated with lung function, exercise capacity, degree of dyspnea, arterial oxygen tension, clinical outcome, risk of exacerbation, and all-cause and COPD-related mortalities [5].…”

Section: Introductionmentioning

confidence: 99%

Association between serum adiponectin concentrations and chronic obstructive pulmonary disease: a meta-analysis

Lin

Jiang

et al. 2020

Bioscience Reports

Self Cite

View full text Add to dashboard Cite

Background: Adiponectin has been implicated to play a role in the pathophysiology of chronic obstructive pulmonary disease (COPD). Many studies have assessed serum adiponectin concentrations in COPD patients. However, results from different reports were not consistent. To assess the association of serum adiponectin concentrations and COPD, a meta-analysis was performed. Methods: PubMed, Embase, Web of Science and Cochrane Library were searched for eligible studies. Data were extracted, and then standard mean differences (SMDs) and 95% confidence intervals (CI) were calculated. Results: Thirteen studies involving a total of 1131 cases and 689 controls were included in this meta-analysis. Combined data indicated that the serum adiponectin levels were higher in COPD patients than those in controls (SMD: 1.09, 95% CI [0.73-1.45], P < 0.001). In the subgroup analyses by disease period, there were similar results in stable COPD patients (SMD: 0.77, 95% CI [0.47-1.07], p <0.001; I 2 = 83.9%, P < 0.001), AECOPD patients (SMD: 2.51, 95% CI [0.71-4.30], P = 0.006; I 2 = 95.2%, P < 0.001) and mixed COPD patients (SMD: 1.21, 95% CI [0.67-1.75], P < 0.001). Furthermore, the serum adiponectin levels were higher in AECOPD patients than those in stable COPD patients (SMD: 1.06, 95% CI [0.13-1.99], P = 0.026). Conclusions: This meta-analysis indicates that patients with COPD have higher serum adiponectin concentration than healthy controls.

show abstract

“…Many clinical symptoms and a high risk of exacerbations were observed in COPD patients of group D[ 15 ], whose CRP values were significantly higher than those in the other three groups[ 16 ]. Thus, a clinical trial was conducted to investigate the effects of tiotropium (Tio) and/or budesonide/formoterol (Bud/Form) on systemic inflammation biomarkers in stable COPD patients of group D and improvements of symptoms and pulmonary function.…”

Section: Introductionmentioning

confidence: 99%

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundThe systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. To investigate the effects of tiotropium (Tio) and/or budesonide/formoterol (Bud/Form) on systemic inflammation biomarkers in stable COPD patients of group D, a randomized, open-label clinical trial was conducted.MethodsEligible participants (n = 324) were randomized and received either Tio 18ug once daily (group I), Bud/Form 160/4.5ug twice daily (group II), Bud/Form 320/9ug twice daily (group III), or Tio 18ug once daily with Bud/Form 160/4.5ug twice daily (group IV) for 6 months. Systemic inflammation biomarkers were measured before randomization and during the treatment, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), serum amyloid A (SAA), tumor necrosis factor-α (TNF-α), fibrinogen (Fib), and white blood cell (WBC).ResultsAfter 6-month treatment, CRP levels in group II, group III and group IV changed by a median (interquartile range) of -1.25 (-3.29, 1.18) mg/L, -1.13 (-2.55, 0.77) mg/L, and -1.56 (-4.64, 0.22) mg/L respectively, all of which with statistical differences compared with group I. In addition, there were no treatment differences in terms of IL-8, SAA, TNF-α, Fib and WBC levels.ConclusionsA long-term treatment with Bud/Form alone or together with Tio can attenuate circulating CRP levels in COPD patients of group D, compared with Tio alone.

show abstract

Serum C-reactive protein level in COPD patients stratified according to GOLD 2011 grading classification

Cited by 5 publications

References 22 publications

Study of Prognostic Association of C-Reactive Protein (A Biomarker) with Clinically Important Predictors of Outcome in Stable and Unstable COPD Patients

Study of Prognostic Association of C-Reactive Protein (A Biomarker) with Clinically Important Predictors of Outcome in Stable and Unstable COPD Patients

Association between serum adiponectin concentrations and chronic obstructive pulmonary disease: a meta-analysis

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D

Contact Info

Product

Resources

About